News
Public · Published
INOVIQ Signs Agreement with Sonic Healthcare to Advance EXO-OC Ovarian Cancer Detection Test
INOVIQ signed a validation and licence option agreement with Sonic Healthcare USA for its EXO-OC ovarian cancer detection test. Sonic can transfer, optimise and validate the test at a New York state laboratory, with an option to seek a future licence to offer it as a laboratory developed test, subject to successful validation and commercial discussions.
Published:
Updated:
What happened
INOVIQ signed a validation and licence option agreement with Sonic Healthcare USA for its EXO-OC ovarian cancer detection test. Sonic can transfer, optimise and validate the test at a New York state laboratory, with an option to seek a future licence to offer it as a laboratory developed test, subject to successful validation and commercial discussions.
Confirmed
Global impact / market context
Sonic’s laboratory work could give INOVIQ a route toward offering EXO-OC through a US testing service, but the licence is not guaranteed. If validation succeeds and commercial discussions lead to a licence, earlier access to the US diagnostics market could create revenue; otherwise, commercialisation may be delayed.
Analyst inference
The agreement places test optimisation and validation alongside INOVIQ’s planned US clinical-sample collection, regulatory work and reimbursement activities. These steps address whether EXO-OC can be validated and offered as a laboratory developed test, a test run by a laboratory rather than sold as an approved commercial kit.
Confirmed
What to watch
- Watch for completion of Sonic’s optimisation and validation work, which tests whether EXO-OC performs well enough to support the proposed laboratory service. Analyst inference
- INOVIQ anticipates the optimisation and validation program needed to advance EXO-OC toward laboratory developed test commercialisation will be finalised by early 2028. Confirmed
- Track whether INOVIQ’s US clinical-sample collection and regulatory and reimbursement activities progress, since setbacks could delay patient access and any revenue from the test. Analyst inference